Eli Lilly will pay up to $1.3bn for Superluminal Medicines to discover and progress small-molecule therapeutics for GPCR ...

Concerns around Ixchiq's safety profile in elderly individuals continue as travel-related chikungunya cases increase in the ...

With multiple novel therapies expected and the treatment paradigm shifting toward earlier intervention, the US EoE market ...

Basilea has acquired the global rights for Venatorx Pharmaceuticals’ ceftibuten-ledaborbactam etzadroxil, an antibiotic being ...

Apertura Gene Therapy has entered several licensing agreements to advance CNS treatments using its TfR1 CapX technology.